

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JOINN LABORATORIES (CHINA) CO., LTD.

北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6127)

PROPOSED ELECTION OF NEW SESSION OF THE BOARD

This announcement is made by Joinn Laboratories (China) Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

PROPOSED ELECTION OF NEW SESSION OF THE BOARD

As the term of the fourth session of the board (the “**Board**”) of directors (the “**Directors**”) of the Company is going to expire, the Company will carry out the election of the fifth session of the Board in accordance with relevant requirements of the articles of association of the Company (the “**Articles of Association**”) and the Company Law of the People's Republic of China (hereinafter referred to as the “**Company Law**”).

The Company is informed that all the members of the fourth session of the Board, namely Ms. Feng Yuxia, Ms. Sun Yunxia, Mr. Gao Dapeng, Mr. Gu Jingliang and Ms. Luo Xi as executive directors; Mr. Zhang Fan, Mr. Yang Changyun, Mr. Yang Fuquan and Mr. Ying Fangtian as independent non-executive Directors (the “**Re-elect Directors**”), have confirmed that they will offer themselves for re-election at the second extraordinary general meeting of 2025 of the Company (the “**EGM**”).

Biographies of each of the Re-elect Directors are set out in Appendix to this announcement.

As at the date of this announcement, save as disclosed in the Appendix, each of the Re-elect Directors, has confirmed that (i) he/she has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) he/she does not hold any other position with the Company or its subsidiaries; (iii) he/she did not hold any directorships in any other listed companies the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years; and (iv) he/she is not interested in nor is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Each of the Re-elect Directors, has confirmed that, as at the date of this announcement, save as disclosed in the Appendix, there are no other matters relating to his/her appointment that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or the Stock Exchange or to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The term of office of the Re-elect Directors of the fifth session of the Board of the Company shall be three years with effect from the date of approval by the Shareholders at the EGM.

Upon due appointment, the above Re-elect Directors will enter into a service contract with the Company respectively, for a term commencing from the date of approval by the Shareholders at the EGM until the expiry of the term of the fifth session of the Board. Details of the remuneration of the Re-elect Directors will be disclosed in the annual report of the Company.

By Order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairperson

Beijing, the PRC
30 October 2025

As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Ms. Sun Yunxia, Mr. Gao Dapeng, Mr. Gu Jingliang and Ms. Luo Xi as executive Directors, and Mr. Zhang Fan, Mr. Yang Changyun, Mr. Yang Fuquan and Mr. Ying Fangtian as independent non-executive Directors.

APPENDIX

BIOGRAPHICAL DETAILS OF DIRECTORS

Executive Directors

Ms. Feng Yuxia (馮宇霞), aged 61, graduated from Academy of Military Medical Sciences (中國人民解放軍軍事醫學科學院) in China with the master of medicine degree in pharmacology in 1992. Ms. Feng practiced as a doctor at the 252nd Hospital of the Chinese People's Liberation Army (中國人民解放軍第252醫院) from August 1986 to August 1989, served at the Institute of Toxicology and Drugs of Chinese Academy of Military Medical Sciences (中國人民解放軍軍事醫學科學院毒物藥物研究所) from August 1992 to August 1995. She previously served as an executive committee member of Alliance of Bio-Box Outsourcing, China (中國生物技術外包服務聯盟). Ms. Feng founded the Company in 1995 and has been holding her position since then, including the general manager and the chairperson of the board of the Company. She currently serves as the chairperson of the board of our Company, responsible for the overall strategic planning of the Company and presiding over the Board affairs.

Ms. Feng and her spouse, Mr. Zhou Zhiwen (“**Mr. Zhou**”), are both controlling shareholders of the Company. As at the date of this announcement, Ms. Feng holds 167,160,633 A Shares of the Company; her spouse Mr. Zhou holds 74,725,981 A Shares.

Ms. Feng's niece is the wife of Mr. Gao Dapeng.

Ms. Sun Yunxia (孫雲霞), aged 57, received her master's degree in medicine from Norman Bethune University of Medical Sciences (白求恩醫科大學), now known as Norman Bethune Health Science Center of Jilin University (吉林大學白求恩醫學部), in China in July 1995. Ms. Sun practiced as the chief physician at Peking University Shougang General Hospital (北京大學首鋼醫院) from July 1995 to September 1999. Ms. Sun joined our company in October 1999, serving successively as the head of toxicology, the director of toxicology department, the director of quality assurance department, the deputy director of organization and so on. Ms. Sun has been engaged in drug safety evaluation for more than 20 years, and has participated in more than 300 studies. She has published more than 30 papers in many industry journals and academic conferences, including Journal of Toxicology (《毒理學雜誌》). Ms. Sun currently serves as executive director and a vice general manager.

As at the date of this announcement, Ms. Sun holds 2,678,907 A Shares of the Company.

Mr. Gao Dapeng (高大鵬), aged 43, received his bachelor's degree in management from Central University of Finance and Economics (中央財經大學) in 2005. Mr. Gao served as an assistant auditor at Beijing Zhongshui Xincheng Tax Firm (北京中稅信誠稅務師事務所) from September 2005 to June 2007, an assistant accountant and the finance manager successively at Staidson (Beijing) Biopharmaceuticals Co., Ltd. (舒泰神(北京)生物製藥股份有限公司) (a company listed on the Shenzhen Stock Exchange with stock code: 300204) from June 2007 to October 2012. Mr. Gao joined the Company in November 2012 and has held positions including finance manager and chief financial officer. Mr. Gao currently serves as executive Director, the general manager, and the secretary to the Board. Mr. Gao is primarily responsible for overseeing the operation, capital management and matters relating to information disclosure of our Group.

As at the date of this announcement, Mr. Gao holds 282,746 A Shares of the Company.

Mr. Gao is the husband of the niece of Ms. Feng.

Mr. Gu Jingliang (顧靜良), aged 45, possesses a master's degree. He joined the Company in April 2006 and has successively served as the head of pharmacodynamics/toxicology, the deputy director and director of drug metabolism laboratory, and the director of marketing and sales department. He is currently the deputy General Manager and Chief Brand Officer of the Company.

As at the date of this announcement, Mr. Gu holds 203,292 A Shares of the Company.

Mr. Gu's spouse is the granddaughter of the aunt of Ms. Feng.

Ms. Luo Xi (羅樺), aged 48, is a Ph.D. of Micrological and Biochemical Pharmacology. From July 2007 to April 2012, Ms. Luo served as an analyst and industry leader of the pharmaceutical industry in the securities research and development department of CSC Financial Co., Ltd.; from May 2012 to March 2015, she worked as an analyst of medical health industry in Zhong De Securities Company Limited (中德證券有限責任公司); from March 2015 to September 2021, she worked as an executive director and joint administrative officer of healthcare group of global investment banking committee in CITIC Securities Co., Ltd. (中信証券股份有限公司); from September 2021 to November 2023, she served as the chief financial officer of CanSino Biologics Inc.. Ms. Luo currently serves as the Director and the deputy general manager of the Company.

Independent Non-executive Directors

Mr. Zhang Fan (張帆), aged 46, graduated from Sun Yat-sen University (中山大學) with a Bachelor's Degree in Management (majoring in accounting) in 2001; he graduated from Carnegie Mellon University with an MBA (master of business administration) degree in 2010; he holds the Certified Public Accountant qualification in the U.S. Mr. Zhang worked at the head office of China Construction Bank (中國建設銀行) from 2001 to 2006, serving at the audit department, the restructuring office and the board of director office respectively, and engaging in internal audit, the shareholding system reform and listing of China Construction Bank, support for the board operations, and investor relations management. From 2010 to 2018, Mr. Zhang worked at CCB International (建銀國際), serving at the investment banking department as a managing director and the head of financial institution business, during which he led the execution of capital market transactions, including listings, additional share issuances, mergers and acquisitions and bond issuances for a number of Chinese financial institutions in Hong Kong. From 2018 to 2019, Mr. Zhang worked at WeShare (新分享科技) as the chief strategy officer, responsible for strategic investment and financing of the company. Mr. Zhang served as a managing director and the head of the institutional business department of Everbright Limited (光大控股) from 2019 to April 2024, in charge of the fundraising, establishment and management of various private equity funds under Everbright Limited, as well as the company's ESG-related work. Since May 2024, he has been the chief executive officer of WeShare Asset Management Limited (新分享資產管理有限公司). Mr. Zhang is an independent non-executive Director of the Company and is mainly involved in the decision-making of the Board.

Mr. Yang Changyun (陽昌雲), aged 55, graduated from Lanzhou Commercial College (now known as Lanzhou University of Finance and Economics) with a Bachelor's Degree in Accounting in June 1993, and obtained a Master's Degree in Accounting from the Institute of Fiscal Science, Ministry of Finance (now known as Chinese Academy of Financial Sciences) in September 1999, and a Ph.D. degree in management (accounting) from the Institute of Fiscal Science, Ministry of Finance (now known as Chinese Academy of Financial Sciences) in September 2011. From July 1993 to September 1999, he served as a lecturer in the Department of Accounting of Ningbo University; from May to November 2000, he served as a project manager of the Investment Banking Department of Guosen Securities Co., Ltd.; from February 2001 to March 2007, he served as manager of the Listed Company Department of Shanghai Stock Exchange; from April 2007 to August 2009, he served as an assistant to the chief executive of Industrial Securities Co., Ltd.; from September 2009 to January 2015, he served as the secretary of the board of directors and the chief financial officer of Hongyuan Securities Co., Ltd.; from January 2015 to December 2020, he served as the deputy general manager, the secretary to the board of directors and the chief financial officer of Shenwan Hongyuan Group Co., Ltd.; from February 2021 to May 2023, he served as the business director of asset management of Guodu Securities Co., Ltd.; from September 2023 to date, he has been the chairman of Beijing Shenrun Private Equity Fund Management Co., Ltd.; from May 2025 to date, he has been the supervisor of Mianyang Runlian Enterprise Management Co., Ltd. (綿陽潤聯企業管理有限公司); from June 2025 to date, he has been the manager of Beijing Lianyang Consulting Co., Ltd. (北京聯陽諮詢有限公司); from September 2025 to date, he has been the supervisor of Jingtianhui (Technology) Co., Ltd. (京天匯(科技)有限公司); from October 2025 to date, he has been the chief financial officer, manager and director of Beijing Shenrun Investment and Management Co., Ltd. (北京坤潤投資管理有限公司). Since 23 January 2025, Mr. Yang has been an independent non-executive Director of the Company and is mainly involved in the decision-making of the Board.

Mr. Yang Fuquan (楊福全), aged 60. He graduated from Zhengzhou University in July 1987, majoring in analytical chemistry, and received a bachelor's degree in science. In December 1992, he graduated from the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, majoring in analytical chemistry, and received a Ph. D degree in science. From December 1992 to June 1995, he engaged in postdoctoral research in the Department of Environmental Chemistry, National Institute of Environmental Research, Japan Environment Agency; from June 1995 to December 2000, he served as an associate researcher at the Beijing Institute of New Technology Applications; from December 2000 to June 2004, he served as a visiting scholar at the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI). From July to August 2006, he served as a senior visiting scholar at the Scripps Research Institute in the United States; from June 2004 to the present, he has been a researcher at the Institute of Biophysics, Chinese Academy of Sciences, a director of the Proteomics Technology Laboratory of the Research Platform for Protein Sciences, a chief scientist of mass spectrometry and a doctoral supervisor; from October 2005 to the present, he has been a member of Chinese Proteomics Professional Committee and a committee member of the Mass Spectrometry Branch of the Chinese Physical Society; from October 2015 to the present, he has been a position professor at the University of Chinese Academy of Sciences and a doctoral supervisor; from October 2017 to the present, he has been a deputy director committee member of the Professional Committee on Extracellular Vesicle Research and Application, Chinese Society of Research Hospitals; from October 2023 to the present, he has been a deputy director member of the Academic Committee of the School of Life Sciences, Beijing University of Chinese Medicine and a member of the First Academic Committee of the National Key Laboratory of Nephrology, the General Hospital of Chinese People's Liberation Army. Since 23 January 2025, he has been an independent non-executive Director of our Company and is mainly involved in the decision-making of the Board.

Mr. Ying Fangtian (應放天), aged 55. He was elected as an academician of the European Academy of Engineering in May 2024 and appointed as the president of the National EcoIndustrial Design Institute (EIDI) in 2020. From July 2005 to August 2010, he served as a deputy director and associate professor of the Department of Industrial Design, the College of Computer Science and Technology, Zhejiang University; from July 2005 to date, he has been a director and professor of the Ministry of Education's Engineering Center for Computer Aided Product Innovation Design (計算機輔助產品創新設計教育部工程中心). Since 23 January 2025, he has been an independent non-executive Director of our Company and is mainly involved in the decision-making of the Board.